Steady plasma concentration of unfractionated heparin reduces infarct volume and prevents inflammatory damage after transient focal cerebral ischemia in the rat

Journal of Neuroscience Research

Volumn 77, Issue 4, 2004, Pages 565-572

  Cervera, Álvaro ^a   Justicia, Carles ^a   Reverter, Joan C ^a   Planas, Anna M ^a   Chamorro, Ángel ^a,b  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

HO 1; IL 10; Inflammation; Ischemia reperfusion; VCAM 1

Indexed keywords

CELL ADHESION MOLECULE; ENDOTHELIAL VASCULAR CELL ADHESION MOLECULE 1; HEME OXYGENASE 1; HEPARIN; INTERLEUKIN 10; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY I 125; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLEEDING; BOLUS INJECTION; BRAIN BLOOD FLOW; BRAIN BLOOD VESSEL; BRAIN HEMORRHAGE; BRAIN INFARCT VOLUME; BRAIN INFARCTION; BRAIN ISCHEMIA; CONTROLLED STUDY; DRUG BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE INDUCTION; INFLAMMATION; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REPERFUSION; STEADY STATE; STROKE; TRANSIENT FOCAL CEREBRAL ISCHEMIA; WESTERN BLOTTING;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BRAIN INFARCTION; CEREBRAL INFARCTION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HEME OXYGENASE (DECYCLIZING); HEME OXYGENASE-1; HEPARIN; INFARCTION, MIDDLE CEREBRAL ARTERY; INTERLEUKIN-10; ISCHEMIC ATTACK, TRANSIENT; MALE; NERVE DEGENERATION; NEUROPROTECTIVE AGENTS; RATS; RATS, SPRAGUE-DAWLEY; VASCULAR CELL ADHESION MOLECULE-1;

EID: 3442889913     PISSN: 03604012     EISSN: None     Source Type: Journal    
DOI: 10.1002/jnr.20186     Document Type: Article

References (51)

1. Al-Sadat A, Sunbulli M, Chaturvedi S. 2002. Use of intravenous heparin by North American neurologists: do the data matter? Stroke 33:1574-1577.
2. Bazzoni G, Beltrán-Nunez A, Mascellani G, Bianchini P, Dejana E, del Maschio A. 1993. Effect of heparin, dermatan sulfate, and oligoderivatives on human polymorphonuclear leukocyte functions. J Lab Clin Med 121:268-275.
3. Bitsch A, Klene W, Murtada L, Prange H, Rieckmann PA. 1998. longitudinal prospective study of soluble adhesion molecules in acute stroke. Stroke 29:2129-2135.
4. Blann A, Kumar P, Krupinski J, McCollum C, Beevers DG, Lip GY. 1999. Soluble intercellular adhesion molecule-1, E-selectin, vascular cell adhesion molecule-1 and von Willebrand factor in stroke. Blood Coagul Fibrinolysis 10:277-284.
5. Bonmann E, Juttler E, Krestel HE, Spranger M. 1998. Heparin inhibits induction of nitric oxide synthase by cytokines in rat brain microvascular endothelial cells. Neurosci Lett 253:95-98.
6. Chamorro A. 1999. Heparin in acute ischemic stroke: the case for a new clinical trial. Cerebrovasc Dis 9(Suppl 3):16-23.
7. Chamorro A. 2001. Immediate anticoagulation in acute focal brain ischemia revisited. Gathering the evidence. Stroke 32:577-578.
8. Chamorro A, Vila N, Ascaso C, Blanc R. 1999. Heparin in acute stroke with atrial fibrillation. Clinical relevance of very early treatment. Arch Neurol 56:1098-1102.
9. Chamorro A, Obach V, Vila N, Revilla M, Cervera A, Ascaso C. 2000. A comparison of the acute-phase response in patients with ischemic stroke treated with high-dose heparin or aspirin. J Neurol Sci 178:18-22.
10. Chamorro A, Cervera A, Castillo J, Dávalos A, Aponte JJ, Planas AM. 2002. Unfractionated heparin is associated with a lower rise of serum vascular cell adhesión molecule-1 in acute ischemic stroke patients. Neurosci Lett 328:229-232.
11. Coull BM, Williams LS, Goldstein LB, Meschia JF, Heitzman D, Chaturvedi S, Johnston KC, Starkman S, Morgenstern LB, Wilterdink JL, Levine SR, Saver JL. 2002. Anticoagulants and antiplatelet agents in acute ischemic stroke: report of the joint Stroke Guideline Development Committee of the American Academy of Neurology and the American Stroke Association (a division of the American Heart Association). Stroke 33:1934-1942.
12. Dandona P, Qutob T, Hamouda W, Bakri F, Aljada A, Kumbkarni Y. 1999. Heparin inhibits reactive oxygen species generation by polymorphonuclear and mononuclear leucocytes. Thromb Res 96:437-443.
13. del Zoppo GJ, Schmid-Schonbein GW, Mori E, Copeland BR, Chang CM. 1991. Polymorphonuclear leukocytes occlude capillaries following middle cerebral artery occlusion and reperfusion in baboons. Stroke 22:1276-1283.
14. Diamond MS, Alon R, Parkos CA, Quinn MT, Springer TA. 1995. Heparin is an adhesive ligand for the leukocyte integrin Mac-1 (CD11b/CD18). J Cell Biol 130:1473-1482.
15. Dirnagl U, Iadecola C, Moskowitz MA. 1999. Pathobiology of ischemic stroke: an integrated view. Trends Neurosci 22:391-397.
16. Edwards RL, Rickles FR, Bobrove AM. 1979. Mononuclear cell tissue factor: cell of origin and requirements for activation. Blood 54:359-370.
17. Fauconneau B, Petegnief V, Sanfeliu C, Piriou A, Planas AM. 2002. Induction of heat shock proteins (HSPs) by sodium arsenite in cultured astrocytes and reduction of hydrogen peroxide-induced cell death. J Neurochem 83:1338-1348.
18. Grosser N, Abate A, Oberle S, Vreman HJ, Dennery PA, Becker JC, Pohle T, Seidman DS, Schroder H. 2003. Heme oxygenase-1 induction may explain the antioxidant profile of aspirin. Biochem Biophys Res Commun 308:956-960.
19. Gubitz G, Counsell C, Sandercock P, Signorini D. 2000. Anticoagulants for acute ischemic stroke (Cochrane Review). In: The Cochrane Library, issue 3. Oxford: Update Software.
20. Hogasen AK, Abrahamsen TG. 1995. Heparin suppresses lipopolysaccharide- induced monocyte production of several cytokines, but simultaneously stimulates C3 production. Thromb Res 80:179-184.
21. International Stroke Trial Collaborative Group. 1997. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, heparin, both, or neither among 19435 patients with acute ischemic stroke. Lancet 349:1569-1581.
22. Justicia C, Pérez-Asensio FJ, Burguete MC, Salom JB, Planas AM. 2001. Administration of transforming growth factor-α reduces infarct volume after transient focal cerebral ischemia in the rat. J Cereb Blood Flow Metab 21:1097-1104.
23. Kochanek PM, Hallenbeck JM. 1992. Polymorphonuclear leukocytes and monocytes/macrophages in the pathogenesis of cerebral ischemia and stroke. Stroke 23:1367-1379.
24. Koenig A, Norgard-Sumnicht K, Linhardt R, Varki A. 1998. Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins. Implications for the use of unfracdonated and low molecular weight heparins as therapeutic agents. J Clin Invest 101:877-889.
25. Lever R, Page CP. 2002. Novel drug development opportunities for heparin. Nat Rev Drug Discov 1:140-148.
26. Lever R, Hoult JR, Page CP. 2000. The effects of heparin and related molecules upon the adhesion of human polymorphonuclear leucocytes to vascular endothelium in vitro. Br J Pharmacol 129:533-540.
27. Ley K, Cerrito M, Arfors KE. 1991. Sulfated polysaccharides inhibit leukocyte rolling in rabbit mesentery venules. Am J Physiol 260:H1667-H1673.
28. Major Ongoing Stroke Trials. 2003. Stroke 34:e1-e12.
29. Mazza F, Goodman A, Lombardo G, Vanella A, Abraham NG. 2003. Heme oxygenase-1 gene expression attenuates angiotensin II-mediated DNA damage in endothelial cells. Exp Biol Med 228:576-583.
30. McGilvray ID, Lu Z, Bitar R, Dackiw APB, Davreux CJ, Rotsein OD. 1997. VLA-4 integrin cross-linking on human monocytic THP-1 cells induces tissue factor expression by a mechanism involving mitogen-activated protein kinase. J Biol Chem 272:10287-10294.
31. Melo LG, Agrawal R, Zhang L, Rezvani M, Mangi AA, Ehsan A, Griese DP, Dell'Acqua G, Mann MJ, Oyama J, Yet SF, Layne MD, Perrella MA, Dzau VJ. 2002. Gene therapy strategy for long-term myocardial protection using adeno-associated virus-mediated delivery of heme oxygenase gene. Circulation 105:602-607.
32. Minter AJ, Keoshkerian E, Chesterman CN, Dawes J. 1996. Fibroblast growth factor and heparin protect endothelial cells from the effects of interleukin 1. J Cell Physiol 167:229-237.
33. Panahian N, Yoshiura M, Maines MD. 1999. Overexpression of heme oxygenase-1 is neuroprotective in a model of permanent middle cerebral artery occlusion in transgenic mice. J Neurochem 72:1187-1203.
34. Pernerstorfer T, Hansen JB, Knechtelsdorfer M, Stohlawetz P, Graninger W, Eichler HG, Speiser W, Jilma B. 1999. Heparin blunts endotoxin-induced coagulation activation. Circulation 100:2485-2490.
35. Ryu KH, Hindmanm BJ, Reasoner DK, Dexter F. 1996. Heparin reduces neurological impairment after cerebral arterial air embolism in the rabbit. Stroke 27:303-310.
36. Sans M, Panes J, Ardite E, Elizalde JI, Arce Y, Elena M, Palacin A, Fernandez-Checa JC, Anderson DC, Lobb R, Pique JM. 1999. VCAM-1 and ICAM-1 mediate leukocyte-endothelial cell adhesion in rat experimental colitis. Gastroenterology 116:874-883.
37. Sharp FR, Massa SM, Swanson RA. 1999 Heat-shock protein protection. Trends Neurosci 22:97-99.
38. Sherman DG, Dyken ML Jr, Gent M, Harrison MJG, Hart RG, Mohr JP. 1995. Antithrombotic therapy for cerebrovascular disorders. An update. Chest 108(Suppl):444S-456S.
39. Silvestro L, Viano I, Macario M, Colangelo D, Montrucchio G, Panico S, Fantozzi R. 1994. Effects of heparin and its desultated derivatives on leukocyce-endothelial adhesion. Semin Thromb Hemost 20:254-258.
40. Soriano MA, Sanz O, Ferrer I, Planas AM. 1997. Cortical infarct volume is dependent on the ischemic reduction of perifocal cerebral blood flow in a three-vessel intraluminal MCA occlusion/reperfusion model in the rat. Brain Res 747:273-278.
41. Spera PA, Ellison JA, Feuerstein GZ, Barone FC. 1998. IL-10 reduces rat brain injury following focal stroke. Neurosci Lett 251:189-192.
42. Tedgui A, Mallar Z. 2001. Anti-inflammatory mechanisms in the vascular wall. Circ Res 88:877-887.
43. Tyrrell DJ, Horne AP, Holme KR, Preuss JMH, Page CP. 1999. Heparin in inflammation: potential therapeutic applications beyond anticoagulation. Adv Pharmacol 46:151-208.
44. Vila N, Castillo J, Davalos A, Chamorro A. 2000. Proinflammatory cytokines and early stroke progression. Stroke 31:2325-2329.
45. Vila N, Castillo J, Davalos A, Esteve A, Planas AM, Chamorro A. 2003. Levels of anti-inflammatory cytokines and neurological worsening in acute ischemic stroke. Stroke 34:671-675.
46. Wang L, Brown JR, Varki A, Esko JD. 2002. Heparin's anti-inflammatory effects require glucosamine 6-O-sulfation and are mediated by blockade of L- and P-selectins. J Clin Invest 110:127-136.
47. + hematopoietic precursor cells with early myeloid and B-lymphoid cell phenotypes. Blood 82:2649-2663.
48. Xie X, Thorlacius H, Raud J, Hedqvist P, Lindbom L. 1997. Inhibitory effect of locally administered heparin on leukocyte rolling and chemoattractant-induced firm adhesion in rat mesenteric venules in vivo. Br J Pharmacol 122:906-910.
49. Yanaka K, Spellman SR, McCarthy JB, Oegema TR, Low WC, Camarata PJ. 1996a. Reduction of brain injury using heparin to inhibit leukocyte accumulation in a rat model of transient focal cerebral ischemia. I. Protective mechanism. J Neurosurg 85:1102-1107.
50. Yanaka K, Spellman R, McCarthy JB, Low WC, Camarata PJ. 1996b. Reduction of brain injury using heparin to inhibit leukocyte accumulation in a rat model of transient focal cerebral ischemia. II. Dose-response effect and the therapeutic window. J Neurosurg 85:1108-1112.
51. Yates EA, Guimond SE, Turnbull JE. 2004. Highly diverse heparan sulfate analogue libraries: providing access to expanded areas of sequence space for bioactivity screening. J Med Chem 47:277-280.